How to overcome the challenges of manual read-across when assessing nitrosamine acceptable intake limits
Nitrosamines, a class of chemical compounds known for their potential carcinogenic properties, have become a significant concern for the pharmaceutical industry. In line with revised guidance from the European Medicines Agency (EMA), regulatory agencies require N-nitrosamines risk assessments to be performed on all marketed medical products investigating nitrosamine formation potential and their mutagenic and carcinogenic […]